News

Molecular Classification to Predict Prognosis and Relapse Patterns Among Patients With Low/Intermediate-Risk Endometrial Cancer

02/13/2024

Stephanie Holland ;

Results from a retrospective cohort study found that molecular classification can predict prognosis and relapse patterns among patients with low or intermediate-risk endometrial cancer.

Results from a retrospective...

02/13/2024

Oncology

News

Selinexor Maintenance Therapy Improved PFS Among Patients With TP53 Wild-Type Advanced or Recurrent Endometrial Cancer

10/12/2023

Stephanie Holland ;

Results from an exploratory analysis of the ENGOT-EN5/GOG-3055/SIENDO study identified that selinexor maintenance therapy improved PFS among patients with TP53 wild-type advanced or recurrent endometrial cancer.

Results from an exploratory...

10/12/2023

Oncology

News

Statistical Significance, Prognostic Precision of 2023 FIGO Staging System for Pre-Treated, Early-Stage Endometrial Cancer

09/19/2023

Stephanie Holland ;

According to results of a retrospective study, the 2023 FIGO staging system led to statistically significant stage shifts and higher prognostic precision among patients with pre-treated, early-stage endometrial cancer.

According to results of a...

09/19/2023

Oncology

News

Molecular Classification Predicts Radiotherapy Benefit in Early-Stage Endometrioid Endometrial Cancer

08/29/2023

Stephanie Holland ;

According to an analysis of data from the PORTEC-1 and PORTEC-2 trials, molecular classification can predict response to radiotherapy in early-stage endometrioid endometrial cancer.

According to an analysis of data...

08/29/2023

Oncology

News

Selinexor Maintenance Therapy Demonstrated Durable PFS Benefit Among Patients With Advanced or Recurrent TP53 Wild-Type Endometrial Cancer

08/10/2023

Stephanie Holland ;

According to long-term follow-up results from the phase 3 SIENDO trial, selinexor maintenance prior to systemic therapy showed durable PFS benefit among patients with advanced or recurrent TP53wt endometrial cancer.

According to long-term follow-up...

08/10/2023

Oncology

News

Dostarlimab With Carboplatin–Paclitaxel Prolonged Progression-Free Survival Among Patients With Primary Advanced or Recurrent Endometrial Cancer

08/02/2023

Amber Denham ;

Dostarlimab with carboplatin–paclitaxel significantly increased progression-free survival among patients with primary advanced or recurrent endometrial cancer.

Dostarlimab with...

08/02/2023

Oncology

News

FDA Approves Dostarlimab Plus Carboplatin and Paclitaxel for Advanced or Recurrent dMMR/MSI-H Endometrial Cancer

08/01/2023

Stephanie Holland ;

Based on findings from the RUBY trial, the FDA has approved dostarlimab-gxly plus carboplatin and paclitaxel for adult patients with advanced or recurrent dMMR/MSI-H endometrial cancer.

Based on findings from the RUBY...

08/01/2023

Oncology

News

Pembrolizumab With Chemotherapy in Advanced or Recurrent Endometrial Cancer

07/24/2023

Amber Denham ;

The combination of pembrolizumab with standard chemotherapy resulted in significantly longer progression-free survival among patients with advanced or recurrent endometrial cancer, compared with chemotherapy alone.

The combination of pembrolizumab...

07/24/2023

Oncology

Mansoor Raza Mirza, MD, Copenhagen University Hospital, Denmark

Conference Coverage

Beyond Immunotherapy Treatment for Patients With Recurrent Metastatic Endometrial Cancer

02/24/2023

At the 2023 ESMO Gynecological Cancers Congress, Mansoor Raza Mirza, MD, discusses the role of HER2, p53, and other molecular targets in treating patients with recurrent, metastatic endometrial cancer.

At the 2023 ESMO Gynecological...

02/24/2023

Oncology

News

Lenvatinib Plus Pembrolizumab Demonstrates Long-Term Efficacy, Safety in Advanced Endometrial Carcinoma

02/16/2023

Derek Cowsert ;

Updated study results find lenvatinib plus pembrolizumab exhibits long-term safety and efficacy for patients with previously treated advanced endometrial carcinoma.

Updated study results find...

02/16/2023

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology